BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...
European Space Agency (ESA) astronaut Thomas Pesquet removes the Protein Crystallization Facility hardware from an incubator ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...
Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback